Figure 3.
Kaplan‐Meier plots of progression‐free survival in patients with grade 1–2 gastroenteropancreatic neuroendocrine tumors on somatostatin analog (SSA) monotherapy based on 68Ga‐DOTATATE maximum SUV (SUVmax) cutoff of 18.35. Progression‐free survival was significantly shorter in the low SUVmax group, both among all 108 patients (p < .0001 on Mantel‐Cox test) (A) and among 30 SSA‐naïve patients (p = .019) (B). Abbreviation: SUV, standardized uptake value.